Navigation Links
Controversial Levis jean ad to be withdrawn

It was an ad with a macabre sense of humour. It stirred up a controversy. Now it is being withdrawn from televisions all over the United States. Levis Strauss officially announced that the advertisement in question might not be used again. This followed complaints from many who felt that they did not enjoy the advertisement poking fun at organ donation.

The ad shows an unconscious man falling from a carousel horse. A team of medics approaches him and finds he has a jeans donor card. They take his pants, put them in a cooler like ones often used to transport human organs and take the package by helicopter to a man found cowering in his bedroom. The man dons the pants and seems elated to have them.

This ad film has stirred a hornets nest in a country where nearly a hundred thousand people are on the waiting list awaiting a suitable donor for organ donation. Nearly 20 people die each day because they are unable to find a suitable match.

A spokeswoman for Levis Strauss in San Francisco, said that the ad film was meant in good humour to show how attached some people are with their jeans.

But respecting the popular opinion the ad is being shelved. So much so for a jeans ad. In the end it was Levis, which was given a dressing down!!!
'"/>




Page: 1

Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Controversial deal on public access of the human genome map
3. GMC Gives Controversial Fertility Doctor, A Clean Chit
4. Controversial Theory Says DNA Can Be Pushed To "Dark States"
5. Harvard Begins Controversial Human Stem Cell Cloning Project
6. Controversial Vaccine Raises Fury of the Church
7. The Controversial Stem Cell Transplant Surgery a Failure, Patient died
8. USDA Gives Go-Ahead to Market Controversial Genetically Engineered Rice, LL601
9. Ever-Controversial Mental Health Act To Be Decided Upon
10. User charges imposed on AIIMS patients may be withdrawn
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Controversial Levis jean withdrawn

(Date:5/16/2008)...re-USNewswire/ -- This release is,being sent in a ... with the,National Cancer Institute, part of the N... American Society of Clinical,Oncology meeting in ...ctice,in about 25 percent of patients with colon c... way colorectal cancers will be staged., * This n...
(Date:5/16/2008)...ers, WASHINGTON, May 16 /PRNewswire-USNewswire/ -...echnicians in the Greater Portland, Oregon and,Van...ever contract as,Teamsters., "The Teamsters are p...ong contract that gives them job protection and a ...President Jim Hoffa., The workers, both full-time...
(Date:5/16/2008)...icenter Phase III clinical trial has found that th...) significantly delays cancer progression in patie...d worsened on other treatments. The study was led...emorial Sloan-Kettering Cancer Center (MSKCC), who... meeting of the American Society for Clinical Onco...
(Date:5/16/2008)... care medicine is in a precipitous decline, David ...ge of Physicians (ACP), today joined with leading...ue a call for comprehensive reforms to attract, re...ary care physicians. , During a panel discussio...., Dr. Dale and other panelists spoke about the ch...
Breaking Medicine News(10 mins):Health News:New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer 2Health News:Drug fends off kidney cancer progression 2Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2
... confirmed the death of a Madison County resident ... in 2007 and it seems to be much earlier than the... due to the virus. Four Mississippians have contr...other state has had a case, according to the Healt...
...ve birth to twins at a hospital in London, where s...day, June 9. The 47-year-old and her husband of ...twins, that were due to arrive only next month. P...ival of twins, Chadha also said that her family ha...
... intake of calcium and vitamin D could reduce the ... The four-year clinical trial included more than o...ee supplement groups: calcium) plus vitamin D, cal...rs found that the risk of developing cancer was 60...
...ure Organization (FAO) has warned that diverting f...s would damage biodiversity and lead to a serious ...ve to cope with a nine percent rise on food import... most, will pay an extra 10 percent", the FAO repo...
Other Medicine News:Health News:First Case of West Nile Virus Death in Madison County 2Health News:High Intake of Milk may Reduce Cancer Risks by 60 Percent 2
(Date:5/15/2008)...Phase II Data Presented at ASCO Showed Acceptable ...ce of Grade 3 and 4 Neuropathy, WOODCLIFF LAKE, N...emotherapeutic agent eribulin mesylate (E7389) dem...ion of women with locally advanced or metastatic,b...er Phase II clinical,trial. The study also suggest...
(Date:5/15/2008)...ood pressure reductions demonstrated in Blacks, Hi...etes and Obese Individuals, PARSIPPANY, N.J., May...d today that data presented at the American Societ...c Meeting (ASH 2008) in New,Orleans demonstrated t...pine and olmesartan medoxomil) safely and effectiv...
(Date:5/15/2008)... APPENZELL, Switzerland, May 15 /- E...es Food and Drug Administration (FDA) has,granted ...ment of pulmonary,arterial hypertension (PAH). Ter...ivotal Phase II trial in Europe., "The FDA,s gran...encourages and strengthens our development program...
(Date:5/15/2008)...nsiderable Opportunity Remains for an Antiplatelet... Bleeding than the Combination of Plavix/Iscover ...ision Resources, WALTHAM, Mass., May 15 /PRNewswi...ing research and advisory firms for pharmaceutical...Eli Lilly,s Effient offers,improvement in patient ...
Breaking Medicine Technology:Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3American Society for Microbiology 108th General Meeting 2807 1American Society for Microbiology 108th General Meeting 2807 2Claimsnet Announces Agreement With Aetna for Electronic Claims and Remittance Processing 16244 1Claimsnet Announces Agreement With Aetna for Electronic Claims and Remittance Processing 16244 2New Study Shows the Use of MEDIHONEY 28TM 29 Wound 26 Burn Dressing is Associated With Reduction in Wound Size 16241 1New Study Shows the Use of MEDIHONEY 28TM 29 Wound 26 Burn Dressing is Associated With Reduction in Wound Size 16241 2New Study Shows the Use of MEDIHONEY 28TM 29 Wound 26 Burn Dressing is Associated With Reduction in Wound Size 16241 3New Study Shows the Use of MEDIHONEY 28TM 29 Wound 26 Burn Dressing is Associated With Reduction in Wound Size 16241 4Microwave Treatments for Enlarged Prostate Cause Blood Pressure Surges 1709 1Microwave Treatments for Enlarged Prostate Cause Blood Pressure Surges 1709 2Microwave Treatments for Enlarged Prostate Cause Blood Pressure Surges 1709 3
...r 26, 2007 - Aeolus,Pharmaceuticals, Inc. (OTCBB:A... 18, 2007 issue of the Journal of Neuroscience a s...and National Jewish,Medical and Research Center de...ble catalytic antioxidant, AEOL 11207, demonstrate...s disease ("PD").,The study also showed that the c...
...ss of Hypertension,Treatment Valsartan in Preventi...YO, April 26, 2007 /Xinhua-PRNewswire/ -- The clin...scale clinical trial,headed by the Jikei Universit...nternationally renowned medical journal The,Lancet...s one of,the largest cardiovascular intervention t...
Other Medicine Technology:Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience 2Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience 3First Controlled Large-Scale Intervention Angiotensin Receptor,Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study,Demonstrates Significant Reduction in Blood Pressure and Protection,of Organs with Valsartan 2First Controlled Large-Scale Intervention Angiotensin Receptor,Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study,Demonstrates Significant Reduction in Blood Pressure and Protection,of Organs with Valsartan 3First Controlled Large-Scale Intervention Angiotensin Receptor,Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study,Demonstrates Significant Reduction in Blood Pressure and Protection,of Organs with Valsartan 4
...Tosoh, innovators of automated random access immun...atured system which builds on the proven reliabili...nced automation, optimum sensitivity, rapid result...Test Menu: Thyroid: TSH TT3 T4 FT3 FT4 T-U...
The FastPack system is a state of the art, lab quality immunoassay system designed for rapid results. The FastPack system delivers lab-quality sensitivity at a fraction of the cost of laboratory.
...itros ECi brings true automation and continuous ra...ng. Highly sensitive assays for thyroid, anemia, c...bone metabolism testing are currently available, w...he Vitros ECi can simultaneously process 60 access...
The Vitros 250 is a flexible system that can meet requirements in multiple environments small hospitals, backup in large hospitals, clinics and satellite locations. The Vitros 250 also features on-b
Medicine Products: